Abstract DNA damage is a form of cell stress and injury. Increased systemic DNA damage is related to the pathogenic development of neurodegenerative diseases. Depression occurs in a relatively high percentage of patients suffering from degenerative diseases, for whom antidepressants are often used to relieve depressive symptoms. However, few studies have attempted to elucidate why different groups of antidepressants have similar effects on relieving symptoms of depression. Previously, we demonstrated that neurotoxins N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4)-and camptothecin (CPT) induced the DNA damage response in SH-SY5Y cells, and DSP4 caused cell cycle arrest which was predominately in the S-phase. The present study shows that CPT treatment also resulted in similar cell cycle arrest. Some classic antidepressants could reduce the DNA damage response induced by DSP4 or CPT in SH-SY5Y cells. Cell viability examination demonstrated that both DSP4 and CPT caused cell death, which was prevented by spontaneous administration of some tested antidepressants. Flow cytometric analysis demonstrated that a majority of the tested antidepressants protect cells from being arrested in S-phase. These results suggest that blocking the DNA damage response may be an important pharmacologic characteristic of antidepressants. Exploring the underlying mechanisms may allow for advances in the effort to improve therapeutic strategies for depression appearing in degenerative and psychiatric diseases.
Introduction
DNA damage is a form of cell stress and injury. Neurotoxins have been shown to cause an increase in systemic DNA damage. Physiological and oxidative stresses relate to the pathogenic development of neurodegenerative and psychiatric diseases (Forlenza and Miller 2006; Martin 2008; Rybka et al. 2013) . Progressive neuronal DNA damage in aging brains are closely linked with the onset of neurodegenerative disorders (Lindahl 1993) . Formerly, the brain was a neglected organ in terms of DNA transactions studies. Such neglect was not because the brain was not important, but primarily because adult brain cells are thought to exhibit low levels of DNA synthesis and repair. Over the past two decades, our ever-increasing knowledge of neurological disorders and the striking susceptibility of the brain to oxidative DNA damage have resulted in considerable attention being given to improving our understanding of the brain's DNA repair pathways and genomic stability (Cui et al. 2000; Culmsee et al. 2001; Trushina and McMurray 2007; Kim and Tsai 2009; Jeppesen et al. 2011) . However, pharmacological studies for intervention of DNA damage are limited.
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) has been widely used as a noradrenergic neurotoxin to construct animal models of Alzheimer's disease (AD) and Parkinson's disease (PD) for degeneration of noradrenergic neurons (Srinivasan and Schmidt 2004; Heneka et al. 2006) . Effects of DSP4 on norepinephrine (NE) levels in the peripheral and central noradrenergic system were first reported by Ross several decades ago (Ross 1976) . It was hypothesized that DSP4 selectively damages noradrenergic projections originating from the locus coeruleus (LC) by interacting with the NE reuptake system and depleting intracellular NE, finally inducing degeneration of noradrenergic terminals (Winkler 1976; Ransom et al. 1985; Dooley et al. 1987; Howard et al. 1990; Prieto and Giralt 2001) . Camptothecin (CPT) is another neurotoxin commonly used as an inhibitor of DNA enzyme topoisomerase I (topo I). CPT is found to induce significant, dose-dependent cell death of postmitotic rat cortical neurons in vitro (Morris and Geller 1996) ; additionally, neurotoxic activity of CPT was also found in cultured cerebellar granule neurons (Uday Bhanu and Kondapi 2010) . Aberrant cell cycle activity and DNA damage have been detected during the progression of neurodegenerative conditions. While some components of the cell cycle machinery were found to be upregulated after exposure to severe conditions, such as oxidative stress (Kruman et al. 2004; Murray 2004; Currais et al. 2009 ), many cytotoxic and genotoxic agents including neurotoxins arrest the cell cycle at different phases (Doi 2011) . Previously, we demonstrated that DSP4 induced the DDR in SH-SY5Y cells, resulting in cell cycle arrest predominantly in S-phase (Wang et al. 2014) . Our previous study demonstrated that CPT also induced the DNA damage response (DDR) in SH-SY5Y cells (Wang et al. 2013 ) and primary cultured LC neurons (Wang et al. 2015) . Although there are no data showing that neurotoxin-induced DNA damage plays a role in the development of depression, it has been reported that oxidative stress-generated DNA/RNA damage is associated with the pathogenic process of depression (Jorgensen et al. 2013) , as well as neurodegenerative diseases (Kulkarni and Wilson 2008; Uttara et al. 2009 ). So far, few studies have demonstrated how to interfere with this neurochemical alteration. Exploring potential pharmacological intervention for neurotoxin-induced DNA damage may shed light on the treatment of neurodegenerative diseases.
It is well documented that DNA damage, as an initial event and if not properly repaired, eventually leads to apoptosis and cell death (Kruman and Schwartz 2008) . Although still an emerging field, there are reports about the relationship between psychiatric diseases and DNA damage (Gidron et al. 2006; Flint et al. 2007; Frey et al. 2007; Hara et al. 2011; Jorgensen et al. 2013) . These studies showed that psychological events or factors such as chronic stress, appraisal variable, and external impediments can lead to DNA damage, which may even be elicited by nontoxic materials via classical conditioning (Irie et al. 2000) . Likely, increased cell death might contribute to the pathogenesis of depression (Duman et al. 1999; Shelton et al. 2011) . Also, apoptosis occurs in certain brain regions following chronic stress in rodent models (McKernan et al. 2009 ). On the other hand, neuronal DNA damage is a common feature of neurodegenerative diseases including PD and AD (Kim and Tsai 2009) , in which excessive apoptosis of specific brain regions including the LC causes neurodegeneration (Su et al. 1994; Jenner and Olanow 1998) . As a fact of the clinical and biological overlap between neuropsychiatry and neurodegeneration, these diseases share common depressive symptoms, with a relatively high prevalence rate and comorbidity (Brown and Jahanshahi 1995; Cummings and Masterman 1999; Lee and Lyketsos 2003) . Depression also severely affects the life quality of AD and PD patients; therefore, it is important to treat symptoms of depression in these patients. An interesting correlation among these diseases is that the dysfunctional LC-NE system is deeply involved in the pathological development of these diseases (Zubenko and Moossy 1988; German et al. 1992; Zarow et al. 2003) . Consistently, our previous study demonstrated that DSP4 reduced the expression of dopamine b-hydroxylase and norepinephrine transporter, two noradrenergic phenotypes, in SH-SY5Y cells, which are mediated by action in DDR (Wang et al. 2014) . Further work showed that CPT treatment also resulted in great DDR in SH-SY5Y cells (Wang et al. 2013 ) and in primary cultures from the rat LC, in which DSP4 exhibited the same effect as in SH-SY5Y cells (unpublished data). These observations not only provide the reasonable basis for using NRIs to treat depressive symptoms occurring in these diseases, but also suggest the necessity to explore the possible relationship between antidepressants and DNA damage caused by exogenous and endogenous toxins.
Antidepressants are used for the treatment of major depressive disorder (Briley and Moret 1993; Martin 2008) and depressive symptoms appearing in other diseases (McNamara and Durso 2006) , either alone or in combination with other medications. The most important classes of antidepressants are the selective serotonin reuptake inhibitors (SSRIs) (Geddes and Cipriani 2004) , serotonin and NE reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). Currently one pharmacological mechanism for most clinically used antidepressants is related to the ''monoamine deficiency,'' a hypothesis proposed also for the etiology of major depressive disorder (Schildkraut 1965) . That is, most antidepressants increase neurotransmitter levels, especially serotonin and NE, in the synapses, which in turn restore the neurotransmission and functions of brains affected by deficiency of these neurotransmitters (Tatsumi et al. 1997; Gillman 2007) . This hypothesis has been challenged due to the conflict between rapid increases in synaptic serotonin and NE levels induced by antidepressants and the delayed appearance of therapeutic efficacy. Therefore, their pharmacological mechanisms remain to be elucidated. Moreover, few studies have focused on why different groups of antidepressants have similar effects on relieving depressive symptoms.
In the present study, we aim to explore the possible intervention of antidepressants on neurotoxin-induced DNA damage and cell cycle arrest by testing different antidepressants in combination with either DSP4 or CPT administered to SH-SY5Y cells. DDR markers cH2AX and phosphor-p53 ser15 were monitored, in addition to examination of the cell cycle. The results demonstrate that the tested antidepressants can prevent or reverse the DDR and cell cycle arrest induced by DSP4 or CPT.
Materials and Methods

Cell Culture and Drug Exposure
The human neuroblastoma cell line SH-SY5Y was used in these experiments. Cells were maintained in a 1:1 mix of RPMI 1640 and F12 media, which was supplemented with 10 % heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 lg/ml) at 37°C in humidified air containing 5 % CO 2 . Culture media and supplements were obtained from Gibco-Invitrogen (Carlsbad, CA, USA). Cells were seeded into 6-well or 100-mm plates. Drug exposures were started 24 h post subculture. DSP4 (Sigma, St Louis, MO, USA) was dissolved in distilled water at 50 mM, then diluted with culture media and added to cells to a final concentration of 50 lM, alone or in combination with antidepressants for the times as indicated in the text. CPT was dissolved in 10 mM dimethyl sulfoxide, then diluted with culture media and added to cells to a final concentration of 10 lM, alone or in combination with antidepressants for the times as indicated in the text. Different antidepressants were used in this study: fluoxetine, reboxetine, desiprimine (DMI), paroxetine, imipramine, amitriptyline, l-deprenyl, and pargyline. The concentration of DSP4 was based on our previous data (Wang et al. 2014) . The concentration of CPT was based on published paper from this department . The selection of antidepressant concentrations is primarily based on the literature (Lai and Yu 1997; Koshimura et al. 2000; Taler et al. 2007; Hisaoka et al. 2008; Leskiewicz et al. 2013; Jantas et al. 2014 ) and our preliminary experiments (see the detail on page 7). Only SH-SY5Y cells prior to passage 15 were used. Trypan blue exclusion assay, which is based on that cells with an intact membrane (live cells) are able to exclude the dye while cells without an intact membrane (dead cells) take up the coloring agent (trypan blue), was used to examine cell viability. Cell viability was 90-95 % in the untreated cells. This assay was also used to examine effects of antidepressants on cell death caused by administration of DSP4 and CPT.
In the present study, different time points were selected for DSP4-induced alteration of DDR and cell cycle arrest. This is based on our preliminary experiments that SH-SY5Y cells were treated with DSP4 (5 or 50 lM) for 2, 4, 8, 12, 16, 18 , and 24 h, respectively. The cell cycle arrest begins to change at 18 h. At 24 h, both concentrations of DSP4 similarly caused cell cycle arrest, which is also reported in our previous study (Wang et al. 2013 ). However, DSP4-induced DDR appeared earlier by relatively higher concentrations (10 and 50 lM) (Wang et al. 2013 ).
Western Blotting Analysis
Whole cell extracts for western blot analysis were prepared by lysing cells in ice-cold Nonidet P-40 (NP-40; Sigma, St Louis, MO, USA) buffer (0.5 % NP-40; 50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 2 mM EDTA) for 30 min, after which nuclei and cell debris were removed by centrifugation at 12,000 rpm for 10 min at 4°C. An equal volume of sodium dodecyl sulfate (SDS) gel-loading buffer then was added to the supernatant and the samples were denatured at 70°C for 5 min. Protein concentrations in cell extracts were quantified prior to addition of the loading buffer with the Micro BCA Protein Assay kit (Thermo Science, Rockford, IL, USA). Proteins (40 lg) were electrophoretically separated on 10 or 15 % SDS-polyacrylamide gels and electro-blotted onto a nitrocellulose membrane (Amersham Life Sciences, Buckinghamshire, UK). For protein detection, the blots were probed with anti-cH2AX antibody (1:1000 dilution, Bethyl Laboratories, Inc., Montgomery, TX, USA), or an anti-phosphop53 ser15 antibody (1:1000 dilution, Cell Signaling Technology, Inc., Danvers, MA, USA). A horseradish peroxidaseconjugated anti-mouse or anti-rabbit antibody (1:5000 dilution; Amersham Life Sciences, Buckinghamshire, UK) was used as the secondary antibody. The membranes were then subjected to enhanced chemiluminescence (Amersham Life Sciences, Buckinghamshire, UK) or super enhanced ECL (Sigma Chemical Co., St Louis, MO, USA) and autoradiography. To check for equal loading and transfer, the membranes were reprobed with a mouse IgG monoclonal anti-ß-actin antibody (1:5000 dilution, Amersham Life Sciences, Buckinghamshire, UK).
Flow Cytometry
SH-SY5Y cells were sub-cultured in a 6-well plate at 2 9 10 4 cells/well, then cells were pretreated with fluoxetine (1 and 5 lM), reboxetine (1 and 5 lM), DMI (1 and 5 lM), paroxetine (1 and 5 lM), imipramine (50 and 100 lM), amitriptyline (10 and 50 lM), and deprenyl (50 and 100 lM) for 1 h, then DSP4 (5 lM) was added for another 24 h. In another experiment, cells were pretreated with 5 lM paroxetine or 10 lM amitriptyline, and then 10 lM CPT was added for another 2 h. Cells were washed with 37°C warm phosphate buffered saline (PBS); 200 ll of 0.25 % trypsin-EDTA (Gibco, Carlsbad, CA, USA) was added per well, and the plate was incubated at 37°C for 1 min. The trypsin was aspirated off and the cells were suspended with 1 ml ice-cold PBS containing 0.5 mM EDTA (PBSE). The cells were collected by centrifugation at 3000 rpm for 10 min at 4°C and fixed by slowly adding 1 ml ice-cold 70 % ethanol to resuspend the cells. The cells were stored at -20°C for overnight, and then collected at 3000 rpm for 10 min at 4°C. The cells were washed once with ice-cold PBSE, then recentrifuged and resuspended in 300 ll of freshly prepared PBSE containing 20 lg/ml propidium iodide (Sigma, St Louis, MO, USA) and 20 lg/ml DNase-free RNase A (Invitrogen, Grand Island, NY, USA). After incubation at 37°C for 30 min, the cells were analyzed on the BD Accuri C6 flow cytometer. The population of G0/G1, S, and G2/M was determined using C6 Flow Cytometer Software. The results are expressed as percentage of the attached cells in each phase.
Statistics
All experimental data are presented in the text and graph as the mean ± SEM. The number of replicates is enumerated in the figure legends. Data were analyzed using one-way analysis of variance (ANOVA), which was followed by a post hoc Newman-Keuls test for planned comparisons.
Results
DSP4-Induced DNA Damage Response can be Reduced by Some Antidepressants
Our previous study demonstrated that DSP4, used as a neurotoxin, induced DDR in SH-SY5Y cells (Wang et al. 2014) . To test the effects of antidepressants on DDR induced by DSP4, SH-SY5Y cells were pretreated with different antidepressants for 1 h before 4 h DSP4 (50 lM) treatment. Antidepressants used were SSRIs (fluoxetine and paroxetine), NRIs (reboxetine), TCAs (imipramine, amitriptyline, and DMI), and monoamine oxidase inhibitors (MAOIs, l-deprenyl, and pargyline). As mentioned in materials and methods, the selection of these antidepressant concentrations is based on the published papers (Lai and Yu 1997; Koshimura et al. 2000; Seymour et al. 2003; Taler et al. 2007; Hisaoka et al. 2008; Fisar et al. 2010 , Leskiewicz et al. 2013 Jantas et al. 2014) , in which different antidepressants in clinically relevant concentrations exhibited neuronal protection without effects on cell viability when used alone in SH-SY5Y cells or PC12 cells. Based on the provided information, we performed preliminary experiments and selected two concentrations for each antidepressant under the present experimental conditions. As shown in Figs. 1, 2, 3, and 4, SSRIs, NRIs, and TCAs when given alone to SH-SY5Y cells did not induce any significant changes in protein levels of cH2AX and phosphor-p53 ser15 , as measured by western blotting. However, administering antidepressants prior to DSP4 treatment significantly attenuated DSP4-induced DDR to lower levels, as compared to the groups of DSP4 alone (for effects on cH2AX: DMI: F 5,12 = 379.6, p \ 0.0001; imipramine: F 5,12 = 212.9, p \ 0.0001). Further analyses revealed several specific outcomes: first, the alleviatory effects of some antidepressants on DSP4-induced DDR seem to be concentration dependent. For example, while both concentrations of DMI (1 and 5 lM), imipramine (50 and 100 lM), amitriptyline (10 and 50 lM), fluoxetine (1 and 5 lM), paroxetine (1 and 5 lM), reboxetine (1 and 5 lM), and l-deprenyl (50 and 100 lM) significantly blocked DSP4-induced increases of cH2AX and phosphor-p53 ser15 , lower concentrations of DMI (1 lM, Fig. 1a, b) , fluoxetine (1 lM, Fig. 2a, b) , and paroxetine (50 lM, Fig. 2e , f) showed more significant effects than the higher concentrations on reducing cH2AX and p-p53 ser15 levels. Furthermore, the effect of amitriptyline (Fig. 1j) , reboxetine (Fig. 3b) , and l-deprenyl (Fig. 4b ) on reducing phosphop53 ser15 accumulation was concentration dependent; second, both l-deprenyl and pargyline are MAOIs that inhibit the activity of monoamine oxidase type B, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. While pargyline (1, 5, 10, and 50 lM) did not have any effects on DSP4-induced DDR in SH-SY5Y cells (Fig. 4e) , l-deprenyl (50 and 100 lM) suppressed DDR (Fig. 4a, b ). The effects of tested antidepressants on DSP4-induced cH2AX and phospho-p53 ser15 protein levels are summarized in Table 1 .
CPT-Induced DNA Damage Response can be Reduced by Selected Antidepressants
CPT is commonly used as a DNA topo I inhibitor to induce DNA double strand breaks . CPT induces significant DDR in SH-SY5Y cells as early as 1 h (Wang Neurotox Res (2015 ) 28:154-170 157 et al. 2013 . In the present study, SH-SY5Y cells were treated with different antidepressants for 1 h, and then CPT (10 lM) was added for another hour. Interestingly, only paroxetine (1 and 5 lM), imipramine (10 and 50 lM), and amitriptyline (50 and 100 lM) could attenuate CPTinduced DDR in SH-SY5Y cells, as shown by reduced expression levels of cH2AX and phospho-p53 ser15 (Fig. 5 ). Based on these results, to further examine the consequence of neurotoxin-induced DNA damage and antidepressants' protective effects, cells were exposed to 5 lM DSP4 or 10 lM CPT, respectively, which were cotreated with some antidepressants in the same way as described above. As shown in Fig. 6 , DMI and fluoxetine can prevent DSP4-induced cell death, while paroxetine and amitriptyline partially attenuated CPT-caused cell death, indicating that these antidepressants have neuronal protective effects against neurotoxin-induced cell death.
Effects of Selective Antidepressants on Protecting Cells from S-Phase Arrest
Previously, we showed that DSP4 could arrest SH-SY5Y cells predominately in S-phase (Wang et al. 2014) . To test effects of antidepressants on S-phase arrest caused by DSP4, two parallel experiments were carried out. In the first experiment, which tested effects of antidepressants alone on cell cycles (Fig. 7) , cells were treated with different antidepressants alone for 25 h, or DSP4 alone for 24 h as the positive control. In the second experiment which tested the effect of antidepressants on DSP4-induced alteration of cell cycles (Fig. 8) , cells were pretreated with antidepressants for 1 h, and then DSP4 (5 lM) was added for another 24 h. Cells were then collected and flow cytometric analyses were performed. The results showed that the cells treated with vehicle (the control) distributed 51.7 or 52.1 % in G1-phase (Figs. 7a and 8a ) and 17.6 or 17.8 % in S-phase (Figs. 7b and 8b ). For the groups treated with 5 lM DSP4 only (the positive control), cells were distributed 40.1 or 41.0 % in G1-phase (Figs. 7a and 8a) , and 30.6 or 30.4 % in S-phase (Figs. 7b and 8b) . Compared to the control cells, DSP4 significantly decreased G1-, and increased S-phase cell populations. In contrast, compared to the magnitude of changes in G1-and S-phases caused by DSP4 alone, effects of antidepressants alone on cell cycles were minor. That is, while an increased G1-phase was observed in the cells treated with 5 lM amitriptyline (p \ 0.01), and a reduced, or an increased S-phase population in the cells treated with 5 lM fluoxetine or 1 lM paroxetine (both p \ 0.05), as compared to the control (Fig. 6 ), a majority of tested antidepressants did not affect G1-and S-phases.
Interestingly, as shown in Fig. 8 , SH-SY5Y cells cotreated with DSP4 and antidepressants, DSP4-induced reduction of G1-phase was almost blocked by the most tested antidepressants, such as 1 and 5 lM DMI, 10 lM amitriptyline, 50 and 100 lM imipramine, 5 lM fluoxetine, 1 and 5 lM paroxetine, 1 and 5 lM reboxetine. However, 1 lM fluoxetine, 50 and 100 lM l-deprenyl, 5 and 10 lM pargyline did not show this blockage effect on DSP4-induced alteration in the G1 population. In addition, a similar result was observed in S-phase distribution. Treatment with both concentrations of DMI, amitriptyline, imipramine, paroxetine, and reboxetine abolished DSP4-induced increase of S-phase. DMI and reboxetine completely reversed effects of DSP4. However, the same effect was not observed after co-treatment of DSP4 and fluoxetine. Also, both l-deprenyl and pargyline do not show this effect. These data suggested that selective antidepressants could protect cells from S-phase arrest and increased cell population in G1.
A similar experiment was performed for CPT, as shown in Fig. 9 , 10 lM CPT also resulted in cell cycle arrest in G1/S-phases. Paroxetine (5 lM) and amitriptyline (10 lM) could reverse CPT-induced cell cycle arrest, in agreement with the results shown in Fig. 5 .
Discussion
In the present study, to elucidate the possible drug interference for DSP4/CPT-induced DNA damage, SH-SY5Y cells were co-exposed to neurotoxins and antidepressants with different mechanisms of action. Our results showed that SH-SY5Y cells pretreated with these antidepressants resulted in a relatively common protection of cells from DNA damage and cell death caused by DSP4 and CPT. For example, respective exposure of cells to TCAs, SSRIs, NRIs, and deprenyl blocked DSP4-induced accumulation of cH2AX and phospho-p53 ser15 . Furthermore, pretreatment of cells with imipramine, amitriptyline, and paroxetine also showed a similar attenuation on CPT-induced DNA damage. Flow cytometric analysis confirmed that a majority of the tested antidepressants could prevent or reverse the G1-and S-phase arrest induced by DSP4 and CPT. These results suggest that although these antidepressants have different pharmacologic mechanisms, in regard to their clinical use, they may have a neuronal protective effect against neurotoxin-induced DNA damage, possibly by preventing the cells from arresting predominantly in S-phase. In the present study, almost all tested antidepressants effectively ameliorate DNA damage responses caused by neurotoxins, indicating that blocking neuronal injury caused by DNA damage may be one of their pharmacologic actions for antidepressants. This hypothesis is supported by observations related to pathogenetic processes in major depression disorders, PD, and AD. Some examples include reactive oxygen (ROS) and nitrogen species (RNS), as well as oxidative and nitrosative stress (O&NS), including lipid peroxidation, damaged DNA and proteins, and reduced plasma levels of antioxidants and antioxidant enzymes. A lower total antioxidant capacity is involved in the pathophysiology of depression (Maes et al. 2009 (Maes et al. , 2011 . Similarly, a large body of studies have documented that there is accumulation of oxidative DNA damage in brain cells of patients suffering from AD (Kadioglu et al. 2004 ) and PD (Zhang et al. 1999) . Furthermore, damage and loss of LC noradrenergic neurons are accelerated in AD Bondareff et al. 1987; German et al. 1992; Weinshenker 2008) and PD Rommelfanger and Weinshenker 2007) , representing an early pathological indicator of these diseases. Considering that a dysfunctional LC can play an important role in the development of neurodegenerative diseases, the present data may provide experimental evidence for reasonable explanation for the reason why antidepressants can eliminate depressive symptoms in these diseases.
Our previous study demonstrated that DSP4 induced cell cycle arrest predominantly in S-phase (Wang et al. 2014) . The data from the present work not only confirm this S-phase alteration, but also show that DSP4 treatment results in a reduction of G1-phase cell populations (Figs. 7  and 8 ). The same holds true for short-term CPT treatment (Fig. 9) . Co-treatment with antidepressants and neurotoxins prevented or reversed neurotoxin-induced changes in cell cycle, except for pargyline and deprenyl. Such effects of antidepressants on cell cycle transition are consistent with the recent reports that chronic treatment with different classes of antidepressants down-regulated expression of cell cycle inhibitors (Pechnick et al. , 2011 Epp et al. 2013) , indicating that cell cycle regulation occurs downstream from the primary site of antidepressant action . G1-to S-phase transition is one of the most important steps in the cell cycle. Generally, cell cycle progression is well controlled by the cell cycle machinery, such as cyclins and cyclin-dependent skinases (CDKs) (Xu et al. 2006) . These cyclin/CDK complexes are further negatively regulated by two families of CDK inhibitors, including p21 and p57 (Morgan 1995; Sharpless and DePinho 2004; Gartel and Radhakrishnan 2005) . p21 plays a crucial role in such negative regulation, and its activation consequently leads to restrained proliferation and maintenance of cellular quiescence (Sharpless and DePinho 2004) . Intriguingly, treatment with different classes of antidepressants inhibits the expression of p21, and knockout of p21 attenuates the therapeutic effects of antidepressants in mice (Pechnick et al. , 2011 . Since antidepressants including SSRIs and tricyclics increase cellular proliferation in adult rodent hippocampus (Malberg et al. 2000; Lagace et al. 2007; Green and Galea 2008) , while chronic stress and high glucocorticids reduce cell proferatioin levels (Gould et al. 1997; Brummelte and Galea 2010) , down-regulatory effects of antidepressants on CDK inhibitors of p21 have been interpreted as releasing proliferation restraint and increasing neurogenesis in the brain. Intriguingly, our observations and reports in the literature Pechnick et al. 2008 Pechnick et al. , 2011 Epp et al. 2013 ) may provide evidence to correlate the cell cycle regulation, neurogenesis, antidepressant drugs, and depression.
As for the possible cellular mechanisms underlying the effects of antidepressants on DNA damage and cell cycle, currently we do not have a satisfactory explanation. One nonexclusive possibility to interpret antidepressants' attenuation of DNA damage found in the present study is the neuroprotective role of antidepressants, an important cellular effect reported previously. Actually, such neuroprotective effects appear against different insults. First, antidepressants may protect neurons against neurotoxicity caused by several toxic compounds. For example, fluoxetine suppresses kainic acid-induced neuronal loss in the rat hippocampus, which might be associated with its anti-inflammatory effects. Also, fluoxetine attenuated lipopolysaccharide (LPS)-or 1-methyl-4-phenylpyridinium (MPP ? )-evoked neurotoxicity (Nahon et al. 2005; Zhang et al. 2012 ). Second, it was reported that various antidepressants are able to prevent or reverse apoptotic effects elicited by some types of stress (Drzyzga et al. 2009; McKernan et al. 2009 ). As oxidative insults are involved in stress process, some studies suggest that conventional antidepressants and mood stabilizers may act in part through antioxidant mechanisms Maes et al. 2011) ; conversely, antioxidants have antidepressant properties (Berk et al. 2008; Scapagnini et al. 2012) . Regarding antidepressants' neuroprotection, the survival pathways may play a role, which include the extracellular signal regulated kinase (ERK1/2), phoshpatidyloinositol-3-kinase (PI3 K) (Hetman and Xia 2000) , and cAMP response element binding protein (CREB) (Riccio et al. 1999) , etc. They are not only activated by DNA damage agents and other cellular insults as a defense consequence, but also may provide targets for neuroprotective therapies against these insults. Therefore, the neuroprotective effects accounted by antidepressants, as demonstrated in the present study, may act via these pathways too. It was reported that the antidepressants tianeptine and moclobemide, both MAOIs, prevented apoptosis caused by toxic agent staurosporine, doxorubicin or FasL in vitro through motivating of the ERK1/2 (Chiou et al. 2006; Jantas et al. 2014) . Likewise, imipramine, amitriptyline, DMI, citalopram, fluoxetine, reboxetine, and tianeptine blocked dexamethasone-induced decreases in cell viability and proliferation rate trough activating of ERK1/2 (Leskiewicz et al. 2013) . These antidepressants also protected glia cells from doxorubicin-induced cell death (Jantas et al. 2014) . Furthermore, tianeptine's neuroprotective effects against staurosporine-and doxorubicin-evoked cell death in primary cortical neurons and retinoic acid-differentiated SH-SY5Y cells were found through actuating of MAPK/ERK1/2 and PI3-K/Akt pathways (Jantas et al. 2014) . Also, chronic treatment with DMI, fluoxetine, or imipramine increased phosphorylated CREB in the mouse hippocampus (Thome et al. 2000; Sairanen et al. 2007) , which promote antioxidant activities (Xu et al. 2003) . However, although accumulating evidences support the activation of these signal pathways can benefit the neuroprotection against damaging insults (Hetman and Gozdz 2004) , whether they underlie the effects of antidepressants on DSP4-and CPT-induced DNA damage and cell cycle arrest needs further study.
Although both DSP4 and CPT are cytotoxic agents and their exposure to cells ultimately results in cell death, their cytotoxic mechanisms are different: CPT inhibits DNA enzyme Topo-I and in turn interferes with transcription and translation ; DSP4 mainly depletes norepinephrine and leads to functional degeneration (Ross 1976) . Therefore, their underlying mechanisms, resulting in cell death, are not same. Our experiments showed that CPT-induced cell death occurs earlier and stronger. This may explain why some antidepressants did not protect against CPT-induced DDR as they did in the DSP4 treatment. In the present study, while some antidepressants showed a dose response for action against neurotoxin-induced DDR, other antidepressants (DMI, fluoxetine and paroxetine) showed better efficacy at lower concentrations. This observation is consistent with a previous report in which several antidepressants exhibited an anti-proliferative effect when co-treated with dexamethasone in SH-SY5Y cells in lower concentrations but not in higher concentrations (Leskiewicz et al. 2013 ). This phenomenon may be related to the hypothesis that some antidepressants affect pro-survival pathways only in lower concentrations (Xu et al. 2003) . Also, this notion is supported by previous studies in which chronic administration of antidepressants showed neuroprotective effects at lower doses; when exceeded, no neuroprotection was observed or in some cases cytotoxic effects increased (Xu et al. 2003) . Treatment with a lower concentration of antidepressants, when compared to a higher concentration, has also been shown to highly activate ERK1/2 pathway, as confirmed in other studies (Leskiewicz et al. 2013; Jantas et al. 2014) .
In contrast to our observation, one study showed that except for tianeptine, other tested antidepressants failed to show neuroprotection against staurosporine-and doxorubicin-evoked cell death (Jantas et al. 2014) . One reason b Fig. 5 CPT-induced DDR is blocked by imipramine, amitriptyline, or paroxetine. SH-SY5Y cells were pretreated with imipramine, amitriptyline, or paroxetine for 1 h, then CPT (10 lM) was added for another 1 h. cH2AX and phospho-p53 ser15 were measured as DDR markers. Autoradiographs of western blots are showed in a, d, and g. Quantified analysis data are showed in b, c, e, f, h, and i. The graphic data represent averages obtained from 5 separate experiments (n = 5). for this discrepancy may lie in the fact that different cell lines were used in their experiments (the primary neurons and retinoic aicd-differentiated SH-SY5Y cells) and this study (undifferentiated SH-SY5Y cells). Generally, undifferentiated SH-SY5Y cells are considered as cancer cells and lack many defined neuronal features including neuronal morphology, cell division, and expression of neuron-specific markers (Lombet et al. 2001) . However, retinoic acid-differentiated cells are phenotypically similar to mature neurons. More importantly however, retinoic acid suppresses serotonergic and noradrenergic characteristics (Korecka et al. 2013) , which are the basic pharmacological target for most tested antidepressants. Additionally, retinoic acid can trigger survival signaling (Paillaud et al. 2002; Lee et al. 2006) . Taken together, retinoic acid induces an extensive outgrowth of neuritis, an increased expression of neuronal nuclei, and increased the mitochondrial activity, as well as other neuronspecific markers (Cheung et al. 2009 ), all of which change the response of cells to neurotoxicity. These different observations also indicate that neuroprotective effects may be dependent on the type of antidepressant drugs, cell lines, as well as cell culture conditions used.
It is worth noting that although both l-deprenyl and pargyline were also used in the present study to test the effect on neurotoxin-induced DNA damage, both of these drugs are neither classic nor effective antidepressants (Kennedy et al. 2010) . The results showed that pargyline is the only antidepressant that did not block neurotoxininduced DDR and cell cycle arrest. In contrast, the similar MAOIs l-deprenyl exhibited the same effects on DDR as other antidepressants. Currently, we do not have a satisfactory explanation for this phenomenon. Nevertheless, the current observation is consistent with previous reports: pargyline and l-deprenyl showed different actions to neurotoxins. For example, l-deprenyl (Chiba et al. 1984; Wu et al. 1993; Wadia et al. 1998) but not pargyline (Matsubara et al. 2001 ) had a neuroprotective effect on cells against MPP ? . Also, l-deprenyl pretreatment prevented the depletion of NE induced by DSP4 in the rat hippocampus (Magyar and Haberle 1999) . Moreover, although a recent study demonstrated that pargyline could attenuate cell death by reducing dopamine toxicity (Stansley and Yamamoto 2013) , it has been reported that pargyline does not have an effect on the toxicity caused by administration of L-DOPA (Basma et al. 1995) or BH4 (Choi et al. 2005 ), a chemical known to generate oxidative stress. One explanation is that MAO inhibitive activity of these MAOIs does not account for their effects on neurotoxin-induced cell damage; rather, it depends upon another specific pharmacologic activity. For example, l-deprenyl may protect against MPP ? toxicity by enhancing the activity of antioxidant defense enzymes such as superoxide dismutase and catalase (Knoll 1989; Carrillo et al. 1991; Vizuete et al. 1993) , by inducing a trophic-like substance (Tatton and Greenwood 1991; Seniuk et al. 1994) , or by suppressing hydroxyl radical formation (Wu et al. 1993; Wadia et al. 1998) . Obviously, when comparing l-deprenyl and pargyline, the latter does not have these activities. This may also be the reason why pargyline fails to show significant effects on DSP4-induced DNA damage and cell cycle arrest.
In summary, our present study demonstrated that almost all tested antidepressants with different mechanisms of action can prevent or reverse DSP4/CPT-induced DDR and cell cycle arrest, indicating that the effects of antidepressants against DNA damage may be one of the common mechanisms of action for their clinical use to relieve depressive symptoms appearing in psychiatric and neurodegenerative diseases. These findings may explain why antidepressants with different mechanisms could generally relieve symptoms of depression. Further exploration of these underlying mechanisms may shed light on therapeutic strategies for treatment of these diseases. 
